Skip to main content
OpenTrials
Completed

NCT Number: NCT00904592

A Study on Traditional Chinese Medicine (TCM) Comprehensive Protocol of Prevention and Control in Diabetic Retinopathy

1. Title: A Study on TCM comprehensive protocol of Prevention and Control in Diabetic Retinopathy. 2. Objectives of study: To evaluate the Intervention effect of integrate control protocol on reducing the incidence rate of proliferative diabetic retinopathy, PRP and MVL. Then produce a high performance, optimize, convenient, applicable and demonstrated protocol of integrate control with Intervention of TCM and west medicine. 3. Study Type: Interventional 4. Study Design: Multi-center, Randomized, Blind (Subject, Investigator, Outcomes Assessor), Parallel Assignment, Positive controlled clinical study. 5. Sample size: 480 subjects , divided into test and control groups equally. 6. Primary endpoint: incidence rate of proliferative diabetic retinopathy, panretinal photocoagulation

Completed

Looking for future studies?

Notify Me

Key information

Age range

35 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Chengdu University of TCM

Chengdu, Sichuan, 610075, China

About this study

  • Primary outcome:
  • proliferative diabetic retinopathy
  • panretinal photocoagulation
  • Secondary outcome:
  • Vision, Funduscopy, Fundus photograph
  • Fundus fluorescein angiography
  • Visual Electrophysiology:FERG、OPs、PVEP.
  • Optical coherence tomography.
  • Symptoms scores of TCM.
  • The M0S short-form-36 heaIth survey(SF-36).
  • Visual Function Questionnaire-25(VFQ-25).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosed with diabetes mellitus.
  • Diagnosed with non-proliferative diabetic retinopathy, including moderate and severe diabetic retinopathy
  • and corrected VA≥45 letters(ETDRS), equivalent the decimal value of 0.16(20/125).
  • Diagnosed with the syndrome and signs of TCM.
  • HbA1C≤8.0%.
  • Ages ranged from 35 to 75 years.
  • Joined in the test voluntarily and signed the Informed consent by GCP regulation.

Exclusion criteria

  • Complicating severe vitreous hemorrhage, or requiring laser and vitrectomy treatment.
  • The patients who have been received the therapy of Retina laser photocoagulation.
  • The patients whose dioptric media is so turbid that hard to evaluate the fundus picture.
  • DMKA or other acute metabolic disturbance, or complicating severe acute infection within a month.
  • Combined with other severe Diabetic complication.
  • Having any allergic reaction to some drugs, food and pollen etc. or hypersensitiveness
  • Pregnant or breast feeding.
  • combined with primarily severe diseases such as cardiovascular, hepatic,renal illness ,hemopoietic system disease, and psychosis.
  • Combined with glaucoma, uveitis, ocular neuropathy and severe cataract etc.
  • Participated in other clinical trial within 3 month.

Treatment and study plan

Qi ming granula

Drug

Qi ming granula Usage:4.5g,po,tid. duration:12 months/ arise Endpoint Event

Other names: QM

placebo comparator

Drug

Control group: Basic therapy & placebo

  • Therapy for DM: To control blood glucose, blood pressure, and serum lipid through drug, dietary management , exercise and education.
  • placebo,Usage: 4.5g,po,tid

Other names: PC

Primary outcomes

  1. incidence rate of proliferative diabetic retinopathy, panretinal photocoagulation

    Time frame: 12 months

Secondary outcomes

  1. Symptoms scores of TCM

    Time frame: 12 weeks

Sponsors and collaborators

Lead sponsor

Chengdu University of Traditional Chinese Medicine

Other

Registry information

Official study title

A Study on TCM Comprehensive Protocol of Prevention and Control in Diabetic Retinopathy

Important dates

Study start
2008
Primary completion
2010
Study completion
2011
First posted
May 19, 2009
Registry last updated
Aug 21, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.